These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 15697329)

  • 41. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
    Jorga KM; Nicholl DJ
    Br J Clin Pharmacol; 1999 Sep; 48(3):449-52. PubMed ID: 10510160
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.
    Sabaté M; Bosch A; Pedrós C; Figueras A
    Ann Pharmacother; 1999 Nov; 33(11):1228-9. PubMed ID: 10573327
    [No Abstract]   [Full Text] [Related]  

  • 43. Influence of COMT inhibition on levodopa pharmacology and therapy.
    Goetz CG
    Neurology; 1998 May; 50(5 Suppl 5):S26-30. PubMed ID: 9591519
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
    Jorga KM; Sedek G; Fotteler B; Zürcher G; Nielsen T; Aitken JW
    Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
    [TBL] [Abstract][Full Text] [Related]  

  • 45. COMT inhibition: a new treatment strategy for Parkinson's disease.
    Kurth MC; Adler CH
    Neurology; 1998 May; 50(5 Suppl 5):S3-14. PubMed ID: 9591516
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tolcapone: new drug. In Parkinson's disease: unacceptable risk of severe hepatitis.
    Prescrire Int; 2006 Apr; 15(82):54-7. PubMed ID: 16604736
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
    Davis TL; Roznoski M; Burns RS
    Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
    [TBL] [Abstract][Full Text] [Related]  

  • 48. COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
    Oechsner M; Buhmann C; Strauss J; Stuerenburg HJ
    J Neural Transm (Vienna); 2002; 109(1):69-75. PubMed ID: 11793163
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism.
    Jorga KM; Davis TL; Kurth MC; Saint-Hilaire MH; LeWitt PA; Fotteler B; Zürcher G; Rabbia M
    Clin Neuropharmacol; 2000; 23(2):98-105. PubMed ID: 10803800
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease.
    Factor SA; Molho ES; Feustel PJ; Brown DL; Evans SM
    Clin Neuropharmacol; 2001; 24(5):295-9. PubMed ID: 11586115
    [TBL] [Abstract][Full Text] [Related]  

  • 51. COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
    Gasser UE; Jorga K; Crevoisier C; Hovens SE; van Giersbergen PL
    Eur Neurol; 1999; 41(4):206-11. PubMed ID: 10343151
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Entacapone++ : a new catechol-O-methyltransferase inhibitor which improves the response to levodopa in patients with Parkinson disease and fluctuating motor function].
    Horga de la Parte JF
    Rev Neurol; 1999 Mar 1-15; 28(5):499-504. PubMed ID: 10229966
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease.
    Waters C
    J Am Geriatr Soc; 2000 Jun; 48(6):692-8. PubMed ID: 10855610
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cognitive improvement during Tolcapone treatment in Parkinson's disease.
    Gasparini M; Fabrizio E; Bonifati V; Meco G
    J Neural Transm (Vienna); 1997; 104(8-9):887-94. PubMed ID: 9451720
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.
    Nyholm D; Johansson A; Lennernäs H; Askmark H
    Eur J Neurol; 2012 Jun; 19(6):820-6. PubMed ID: 22136163
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease.
    Lees AJ
    CNS Neurosci Ther; 2008; 14(1):83-93. PubMed ID: 18482101
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
    Katsaiti I; Nixon J
    J Parkinsons Dis; 2018; 8(2):217-231. PubMed ID: 29614697
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New drugs for the treatment of Parkinson's disease.
    LeWitt PA
    Pharmacotherapy; 2000 Jan; 20(1 Pt 2):26S-32S. PubMed ID: 10641989
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tolcapone increases maximum concentration of levodopa.
    Müller T; Woitalla D; Schulz D; Peters S; Kuhn W; Przuntek H
    J Neural Transm (Vienna); 2000; 107(1):113-9. PubMed ID: 10809409
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tolcapone, bromocriptine, and Parkinson's disease. French Tolcapone Study Group.
    Agid Y; Destée A; Durif F; Montastruc JL; Pollak P
    Lancet; 1997 Sep; 350(9079):712-3. PubMed ID: 9291909
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.